Pfizer’s Retacrit undercuts rivals
Executive Summary
Pfizer has launched its Retacrit (epoetin alfa-epbx) biosimilar in the US – the first US biosimilar rival to the Procrit and Epogen epoetin alfa brands for treating anaemia – at a price that undercuts these versions by around three-fifths and more than a third respectively. Highlighting the “substantial discount” represented by Retacrit’s wholesale acquisition cost (WAC) of US$11.03 per 1,000 units/ml, Pfizer noted that this was 57.1% below US$25.72 for Procrit and 33.5% less than US$16.58 for Epogen. Pfizer has a US marketing tie-up with Vifor for Retacrit “in certain channels”.
You may also be interested in...
US Upholds $70m Hospira Epogen Verdict
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.
Biosimilar Safe Harbors Need Record Of Non-Commercial Use, Epogen Ruling Suggests
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.
Pfizer Lines Up Trio Of US Biosimilar Launches
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.